|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khasag O, Boldbaatar G, Tegshee T, Duger
D, Dashdorj A, Uchida T, Matsuhisa T and Yamaoka Y: The prevalence
of helicobacter pylori infection and other risk factors among
mongolian dyspeptic patients who have a high incidence and
mortality rate of gastric cancer. Gut Pathog. 10:142018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shiota S, Murakawi K, Suzuki R, Fujioka T
and Yamaoka Y: Helicobacter pylori infection in Japan. Expert Rev
Gastroenterol Hepatol. 7:35–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Selim JH, Shaheen S, Sheu WC and Hsueh CT:
Targeted and novel therapy in advanced gastric cancer. Exp Hematol
Oncol. 8:252019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wei SC, Duffy CR and Allison JP:
Fundamental mechanisms of immune checkpoint blockade therapy.
Cancer Discov. 8:1069–1086. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y,
Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keir ME, Francisco LM and Sharpe AH: PD-1
and its ligands in T-cell immunity. Curr Opin Immunol. 19:309–314.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guan J, Lim KS, Mekhail T and Chang CC:
Programmed death ligand-1 (PD-L1) expression in the programmed
death receptor-1 (PD-1)/PD-L1 blockade: A key player against
various cancers. Arch Pathol Lab Med. 141:851–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagato T, Ohkuri T, Ohara K, Hirata Y,
Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K,
et al: Programmed death-ligand 1 and its soluble form are highly
expressed in nasal natural killer/T-cell lymphoma: A potential
rationale for immunotherapy. Cancer Immunol Immunother. 66:877–890.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang B, Huang T, Wei H, Shen L, Zhu D, He
W, Chen Q, Zhang H, Li Y, Huang R, et al: The correlation and
prognostic value of serum levels of soluble programmed death
protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in
patients with hepatocellular carcinoma. Cancer Immunol Immunother.
68:353–363. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deng R, Zhang P, Liu W, Zeng X, Ma X, Shi
L, Wang T, Yin Y, Chang W, Zhang P, et al: HDAC is indispensable
for IFN-γ-induced B7-H1 expression in gastric cancer. Clin
Epigenetics. 10:1532018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Union for International Cancer Control, .
Briely JD, Gospodarowicz MK and Wittekind CH: TNM Classification of
Malignant Tumors. 8th. Wiley-Blackwell; Hoboken, NJ: 2017
|
|
17
|
Intlekofer AM and Thompson CB: At the
bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer
immunotherapy. J Leukoc Biol. 94:25–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma J, Zheng B, Goswami S, Meng L, Zhang D,
Cao C, Li T, Zhu F, Ma L, Zhang Z, et al: PD1Hi
CD8+ T cells correlate with exhausted signature and poor
clinical outcome in hepatocellular carcinoma. J Immunother Cancer.
7:3312019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishida M, Iwai Y, Tanaka Y, Okazaki T,
Freeman GJ, Minato N and Honjo T: Differential expression of PD-L1
and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of
lymphohematopoietic tissues. Immunol Lett. 84:57–62. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on t-cell infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Darvin P, Toor SM, Sasidharan Nair V and
Elkord E: Immune checkpoint inhibitors: Recent progress and
potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and
Xu N: Immunohistochemical localization of programmed death-1
ligand-1 (PD-L1) in gastric carcinoma and its clinical
significance. Acta Histochem. 108:19–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and function of the PD-L1 checkpoint. Immunity.
48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shigemori T, Toiyama Y, Okugawa Y,
Yamamoto A, Yin C, Narumi A, Ichikawa T, Ide S, Shimura T, Fujikawa
H, et al: Soluble PD-L1 expression in circulation as a predictive
marker for recurrence and prognosis in gastric cancer: Direct
comparison of the clinical burden between tissue and serum PD-L1
expression. Ann Surg Oncol. 26:876–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18:102019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mimura K, Teh JL, Okayama H, Shiraishi K,
Kua LF, Koh V, Smoot DT, Ashktorab H, Oike T, Suzuki Y, et al:
PD-L1 expression is mainly regulated by interferon gamma associated
with JAK-STAT pathway in gastric cancer. Cancer Sci. 109:43–53.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y
and Zhang P: Interferon-gamma-induced PD-L1 surface expression on
human oral squamous carcinoma via PKD2 signal pathway.
Immunobiology. 217:385–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clark CA, Gupta HB and Curiel TJ: Tumor
cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with
clinical potential. Autophagy. 13:987–988. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qu QX, Xie F, Huang Q and Zhang XG:
Membranous and cytoplasmic expression of PD-L1 in ovarian cancer
cells. Cell Physiol Biochem. 43:1893–1906. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aydin D, Bilici A, Yavuzer D, Kefeli U,
Tan A, Ercelep O, Mert A, Yuksel S, Ozcelik M, Isik D, et al:
Prognostic significance of ADAM17 expression in patients with
gastric cancer who underwent curative gastrectomy. Clin Transl
Oncol. 17:604–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L
and Zhang X: Development of a sandwich ELISA for evaluating soluble
PD-L1 (CD274) in human sera of different ages as well as
supernatants of PD-L1+ cell lines. Cytokine. 56:231–238. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao
F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, et al:
Soluble PD-L1 as a biomarker in malignant melanoma treated with
checkpoint blockade. Cancer Immunol Res. 5:480–492. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu X and Lang J: Soluble PD-1 and PD-L1:
Predictive and prognostic significance in cancer. Oncotarget.
8:97671–97682. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gong B, Kiyotani K, Sakata S, Nagano S,
Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M,
et al: Secreted PD-L1 variants mediate resistance to PD-L1 blockade
therapy in non-small cell lung cancer. J Exp Med. 216:982–1000.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Frigola X, Inman BA, Krco CJ, Liu X,
Harrington SM, Bulur PA, Dietz AB, Dong H and Kwon ED: Soluble
B7-H1: Differences in production between dendritic cells and T
cells. Immunol Lett. 142:78–82. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Frigola X, Inman BA, Lohse CM, Krco CJ,
Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H and Kwon
ED: Identification of a soluble form of B7-H1 that retains
immunosuppressive activity and is associated with aggressive renal
cell carcinoma. Clin Cancer Res. 17:1915–1923. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rossille D, Azzaoui I, Feldman AL, Maurer
MJ, Labouré G, Parrens M, Pangault C, Habermann TM, Ansell SM, Link
BK, et al: Soluble programmed death-ligand 1 as a prognostic
biomarker for overall survival in patients with diffuse large
B-cell lymphoma: A replication study and combined analysis of 508
patients. Leukemia. 31:988–991. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Finkelmeier F, Canli Ö, Tal A, Pleli T,
Trojan J, Schmidt M, Kronenberger B, Zeuzem S, Piiper A, Greten FR
and Waidmann O: High levels of the soluble programmed death-ligand
(sPD-L1) identify hepatocellular carcinoma patients with a poor
prognosis. Eur J Cancer. 59:152–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ito M, Oshima Y, Yajima S, Suzuki T,
Nanami T, Shiratori F, Funahashi K, Nemoto T and Shimada H: Is high
serum programmed death ligand 1 level a risk factor for poor
survival in patients with gastric cancer? Ann Gastroenterol Surg.
2:313–318. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A,
Wu X, Cheng X, Xing X, Du H, et al: Level of circulating PD-L1
expression in patients with advanced gastric cancer and its
clinical implications. Chin J Cancer Res. 26:104–111.
2014.PubMed/NCBI
|
